Biobanking samples for allergic diseases and mast cell disorders
Biobanking for Biomarkers In Respiratory Disease, Allergic Diseases and/or Mast Cell Disorders
This study is collecting samples from people with allergies, asthma, or mast cell disorders to help find new ways to diagnose and treat these conditions in the future.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3200 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse) |
| Trial ID | NCT06037967 on ClinicalTrials.gov |
What this trial studies
This study aims to create a biobank of biological samples from patients with allergic diseases, asthma, or mast cell disorders to support future research. It involves the prospective collection of samples and clinical data, which will be pseudonymised and stored for exploratory studies. The collected data will primarily address questions from the Toulouse University Hospital teams and may also be shared with specialized research teams under legal agreements. This initiative seeks to identify new biomarkers that could enhance diagnosis and treatment in these conditions.
Who should consider this trial
Good fit: Ideal candidates include patients with confirmed allergic conditions, asthma of any severity, or specific mast cell disorders.
Not a fit: Patients without allergic diseases, asthma, or mast cell disorders, or those unable to provide informed consent, may not benefit from this study.
Why it matters
Potential benefit: If successful, this biobank could lead to the discovery of new biomarkers that improve diagnosis and treatment for patients with allergic diseases and mast cell disorders.
How similar studies have performed: Other studies have successfully utilized biobanking approaches to identify biomarkers in similar conditions, indicating a promising avenue for this research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with a positive prick test or specific IgE regardless of the allergen * patients suspected of allergic pathology defined by the need to carry out a prick test or specific IgE or a food or drug reintroduction test as part of the treatment * patients with systemic or cutaneous mastocytosis according to the international classification8 * patients with mast cell activation syndrome according to the international classification8 * patients with familial hyper-alpha tryptasemia on the presence of variation in the number of copies of the alpha allele of the TPSAB1 gene * patients with asthma of any severity * people affiliated or beneficiaries of a social security scheme * patients able to receive and understand the information on the study and their participation and having freely consented to it in writing before any collection of samples or data necessary for the research (no restriction of rights by the judicial authorities and mastery of the French language). Exclusion Criteria: * patients under legal protection, guardianship or curatorship * pregnant or breastfeeding women
Where this trial is running
Toulouse
- Laurent GUILLEMINAULT — Toulouse, France (Recruiting)
Study contacts
- Principal investigator: Laurent GUILLEMINAULT, MD — University Hospital, Toulouse
- Study coordinator: Laurent GUILLEMINAULT, MD
- Email: guilleminault.l@chu-toulouse.fr
- Phone: 05 67 77 17 51
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.